Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.34 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125459 | 0.86 | ATM (0.36) | CNR1NAMPT | |
| SCHEMBL476366 | 0.85 | NAMPT (0.38) | RORCNAMPT | |
| SCHEMBL4137822 | 0.84 | HTR2A (0.39) | RORCNAMPT | |
| SCHEMBL4125774 | 0.83 | SMN1; SMN2 (0.36) | CNR1NAMPTPDE4BSLC16A3SLC16A1 | |
| SCHEMBL4126103 | 0.83 | ALDH1A1 (0.42) | CNR1NAMPT | |
| Hydrochloric Acid SCHEMBL3693726 | 0.82 | RXRA (0.37) | CNR1RORCNAMPT | |
| SCHEMBL3707637 | 0.82 | SLC16A3 (0.37) | CNR1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4135079 | 0.82 | SLC16A3 (0.37) | CNR1PDE4BSLC16A3SLC16A1 | |
| SCHEMBL4126274 | 0.81 | GAA (0.40) | CNR1NAMPTSLC16A3SLC16A1 | |
| SCHEMBL4126825 | 0.80 | P2RX7 (0.36) | CNR1NAMPTSLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | CNR1 938/4885RORC 1168/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.